

Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML

NCT07500441

Status	RECRUITING
Sponsor	Peking University People's Hospital
Enrollment	100 participants

Key Eligibility Criteria

Inclusion (6)

- Diagnosis of acute myeloid leukemia (AML).
- Undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) at the investigating center.
- Negative for recurrent fusion genes routinely monitored in the clinical laboratory, including but not limited to AML1::ETO, CBFB::MYH11, KMT2A (MLL) rearrangements, NUP98::NSD1, NUP98::HOXA9, FUS::ERG, DEK::NUP214, SET::NUP214, PICALM::AF10, and BCR::ABL1.
- Availability of next-generation sequencing (NGS) results at initial diagnosis with accessible original reports.
- Negative for NPM1 mutations at initial diagnosis.
- ... and 1 more (see full listing online)

Exclusion (2)

- Patients with mutation profiles unsuitable for the design of patient-specific digital PCR (dPCR) assays achieving a sensitivity of $\geq 0.1\%$.
- Absence of evaluable molecular targets for longitudinal MRD monitoring.

Locations (1 total)

Peking University People's Hospital, Beijing, Beijing Municipality, China